vs
Aclarion, Inc.（ACON）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Aclarion, Inc.的7611.0倍（$140.6M vs $18.5K）。VERACYTE, INC.净利率更高（29.3% vs -10223.7%，领先10253.0%）。Aclarion, Inc.同比增速更快（80.6% vs 18.5%）。过去两年Aclarion, Inc.的营收复合增速更高（35.2% vs 20.5%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
ACON vs VCYT — 直观对比
营收规模更大
VCYT
是对方的7611.0倍
$18.5K
营收增速更快
ACON
高出62.0%
18.5%
净利率更高
VCYT
高出10253.0%
-10223.7%
两年增速更快
ACON
近两年复合增速
20.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $140.6M |
| 净利润 | $-1.9M | $41.1M |
| 毛利率 | 9.7% | 72.5% |
| 营业利润率 | -10785.8% | 26.4% |
| 净利率 | -10223.7% | 29.3% |
| 营收同比 | 80.6% | 18.5% |
| 净利润同比 | 5.0% | 704.8% |
| 每股收益（稀释后） | $1.39 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONVCYT
| Q4 25 | $18.5K | $140.6M | ||
| Q3 25 | $18.9K | $131.9M | ||
| Q2 25 | $19.3K | $130.2M | ||
| Q1 25 | $19.0K | $114.5M | ||
| Q4 24 | $10.2K | $118.6M | ||
| Q3 24 | $14.4K | $115.9M | ||
| Q2 24 | $11.0K | $114.4M | ||
| Q1 24 | $10.1K | $96.8M |
净利润ACONVCYT
| Q4 25 | $-1.9M | $41.1M | ||
| Q3 25 | $-1.7M | $19.1M | ||
| Q2 25 | $-1.6M | $-980.0K | ||
| Q1 25 | $-2.0M | $7.0M | ||
| Q4 24 | $-2.0M | $5.1M | ||
| Q3 24 | $-1.4M | $15.2M | ||
| Q2 24 | $-1.2M | $5.7M | ||
| Q1 24 | $-2.4M | $-1.9M |
毛利率ACONVCYT
| Q4 25 | 9.7% | 72.5% | ||
| Q3 25 | 23.2% | 69.2% | ||
| Q2 25 | 26.6% | 69.0% | ||
| Q1 25 | -23.6% | 69.5% | ||
| Q4 24 | -100.9% | 66.4% | ||
| Q3 24 | -48.1% | 68.2% | ||
| Q2 24 | -112.3% | 68.1% | ||
| Q1 24 | -92.6% | 64.5% |
营业利润率ACONVCYT
| Q4 25 | -10785.8% | 26.4% | ||
| Q3 25 | -9666.2% | 17.4% | ||
| Q2 25 | -8988.6% | -4.0% | ||
| Q1 25 | -7856.0% | 2.5% | ||
| Q4 24 | -17652.7% | 3.5% | ||
| Q3 24 | -8995.3% | 10.4% | ||
| Q2 24 | -10350.6% | 4.0% | ||
| Q1 24 | -12609.3% | -4.8% |
净利率ACONVCYT
| Q4 25 | -10223.7% | 29.3% | ||
| Q3 25 | -9008.0% | 14.5% | ||
| Q2 25 | -8285.9% | -0.8% | ||
| Q1 25 | -10728.4% | 6.2% | ||
| Q4 24 | -19444.6% | 4.3% | ||
| Q3 24 | -9482.7% | 13.1% | ||
| Q2 24 | -11285.0% | 5.0% | ||
| Q1 24 | -23720.6% | -1.9% |
每股收益（稀释后）ACONVCYT
| Q4 25 | $1.39 | $0.50 | ||
| Q3 25 | $-2.93 | $0.24 | ||
| Q2 25 | $-2.75 | $-0.01 | ||
| Q1 25 | $-9.32 | $0.09 | ||
| Q4 24 | $-809.36 | $0.07 | ||
| Q3 24 | $-1321.49 | $0.19 | ||
| Q2 24 | $-1362.83 | $0.07 | ||
| Q1 24 | $-3985.22 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.8M | $1.3B |
| 总资产 | $13.7M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONVCYT
| Q4 25 | $12.0M | $362.6M | ||
| Q3 25 | $11.3M | $315.6M | ||
| Q2 25 | $12.8M | $219.5M | ||
| Q1 25 | $14.8M | $186.1M | ||
| Q4 24 | $453.7K | $239.1M | ||
| Q3 24 | $1.3M | $274.1M | ||
| Q2 24 | $1.2M | $235.9M | ||
| Q1 24 | $2.1M | $209.2M |
股东权益ACONVCYT
| Q4 25 | $12.8M | $1.3B | ||
| Q3 25 | $12.5M | $1.3B | ||
| Q2 25 | $14.2M | $1.2B | ||
| Q1 25 | $15.8M | $1.2B | ||
| Q4 24 | $970.1K | $1.2B | ||
| Q3 24 | $2.5M | $1.2B | ||
| Q2 24 | $1.6M | $1.1B | ||
| Q1 24 | $2.5M | $1.1B |
总资产ACONVCYT
| Q4 25 | $13.7M | $1.4B | ||
| Q3 25 | $13.2M | $1.4B | ||
| Q2 25 | $14.8M | $1.3B | ||
| Q1 25 | $16.5M | $1.3B | ||
| Q4 24 | $2.1M | $1.3B | ||
| Q3 24 | $3.2M | $1.3B | ||
| Q2 24 | $3.1M | $1.2B | ||
| Q1 24 | $3.7M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $48.8M |
| 自由现金流率自由现金流/营收 | — | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流ACONVCYT
| Q4 25 | $-1.6M | $52.6M | ||
| Q3 25 | $-1.2M | $44.8M | ||
| Q2 25 | $-1.9M | $33.6M | ||
| Q1 25 | $-2.5M | $5.4M | ||
| Q4 24 | $-922.9K | $24.5M | ||
| Q3 24 | $-1.1M | $30.0M | ||
| Q2 24 | $-1.1M | $29.6M | ||
| Q1 24 | $-2.2M | $-9.0M |
自由现金流ACONVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | $-1.2M | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率ACONVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | -6164.6% | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度ACONVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | 38.6% | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率ACONVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
